Comparative Pharmacology
Head-to-head clinical analysis: NORISODRINE AEROTROL versus VAPO ISO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORISODRINE AEROTROL versus VAPO ISO.
NORISODRINE AEROTROL vs VAPO-ISO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Isoproterenol is a non-selective beta-adrenergic receptor agonist, primarily stimulating both β1 and β2 receptors, resulting in increased heart rate, myocardial contractility, and bronchodilation.
VAPO-ISO (isoproterenol) is a non-selective beta-adrenergic agonist that stimulates both beta-1 and beta-2 adrenergic receptors. It increases heart rate, contractility, and conduction velocity (beta-1), and causes bronchodilation and peripheral vasodilation (beta-2).
1 to 2 inhalations (0.08 to 0.16 mg) every 4 to 6 hours as needed for bronchospasm.
Inhalation: 1-2 inhalations of a 0.5% solution for acute bronchospasm; 0.5 mL of 1:200 solution via nebulizer every 4-6 hours as needed.
None Documented
None Documented
The terminal elimination half-life of isoproterenol is approximately 2-3 minutes following intravenous administration, due to rapid uptake into tissues and metabolism by catechol-O-methyltransferase (COMT). This short half-life necessitates continuous infusion for sustained effect.
Terminal elimination half-life is 2–4 hours (mean 3 hours). In severe renal impairment (CrCl <30 mL/min), half-life may be prolonged to 8–12 hours, requiring dose adjustment.
Primarily renal excretion of unchanged drug and metabolites (sulfate conjugates). After intravenous administration, approximately 70-80% of the dose is excreted in urine within 24 hours, with less than 10% in feces.
Renal excretion of unchanged drug (30–50%) and hepatic metabolism to inactive metabolites. Fecal excretion is negligible (<2%).
Category C
Category C
Beta-Adrenergic Agonist
Beta-Adrenergic Agonist